NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED
STATES


Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) a life sciences company
developing stem cell-related technologies, today announced that it is initiating
a marketed offering of units, each unit will be comprised of a common share and
common share purchase warrants in a proportion to be determined. The offering is
to be effected in each of the Canadian provinces of British Columbia, Alberta,
Manitoba, Ontario and Nova Scotia by way of a prospectus supplement to SCT's
base shelf prospectus of March 1, 2011. The number of units to be distributed,
the price of each unit and the exercise price of each whole common share
purchase warrant will be determined in context of the market with final terms to
be determined at the time of pricing. Euro Pacific Canada Inc. is acting as the
agent for the offering.


The purpose of the offering is to provide the resources necessary to conclude
the merger of Trillium Therapeutics Inc. into SCT announced February 4th, 2013
and to permit the exercise of the option by SCT to acquire the license to the
Tigecycline Intellectual Property from the University Health Network, Toronto
announced November 7th, 2012. The assets being acquired and licensed will
conclude the initial step of SCT's published corporate objectives for advancing
the Corporation's interests. 


This news release shall not constitute an offer to sell nor the solicitation of
an offer to buy nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics: 

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) develops stem cell-based
therapeutics through partnerships with research institutions and technology
transfer organizations. SCT's objectives include the sourcing and acquisition of
stem cell-related development opportunities, and securing capital for the
advancement of its licensed or acquired products. The Corporation's intended
corporate acquisitions and licensed acquisitions are positioning it principally
in the field of cancer stem cell therapeutic development. SCT is a member of the
20-member Centre for Commercialization of Regenerative Medicine ("CCRM")
consortium. For more information, visit: www.stemcellthera.com


Forward-Looking Statements

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, SCT's ability to obtain financing in
connection with the proposed arrangement; uncertainties as to the timing of the
arrangement; the satisfaction of the conditions precedent to the completion of
the arrangement; changing market conditions; the successful and timely
completion of pre-clinical and clinical studies; the establishment of corporate
alliances; the impact of competitive products and pricing; new product
development risks; uncertainties related to the regulatory approval process or
the ability to obtain drug product in sufficient quantity or at standards
acceptable to health regulatory authorities to complete clinical trials or to
meet commercial demand; and other risks detailed from time to time in SCT's
ongoing quarterly and annual reporting. Except as required by applicable
securities laws, SCT undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
+1 647 258 4325
DAllan@StemCellThera.com
www.StemCellThera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.